Research Papers
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
16 June 2021
Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there…
Should We ‘Drop Dead’ from Health State Valuation?
10 December 2020
In a new OHE Research Paper, Chris Sampson, David Parkin, and Nancy Devlin consider whether ‘dead’ must be used as an anchor in health state valuation.…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides…
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
20 January 2020
This OHE Research Paper describes a study in which four stated preference methods for anchoring EQ-5D-Y values were compared: visual analogue scale, discrete choice experiment (with…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
A new OHE Research Paper summarises the findings of a project funded by the Wellcome Trust on innovative HTA methods and contracting for antibiotics. The paper…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…
Can We Really Compare and Aggregate Patient-reported Outcomes Between People and Settings?
11 April 2019
A new OHE Research Paper considers whether we can compare and aggregate patient-reported outcome (PRO) data between people and settings. The paper is authored by Nancy…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
Transparency as a principle of good governance is not the same as transparency for improving access by lowering prices. In fact, the former often carries an…